Hundreds of FDA-mandated post-market studies for approved drugs and medical devices are running behind schedule, highlighting regulatory challenges as the agency increasingly relies on post-approval research to address unresolved safety and efficacy questions.
The issue has gained renewed attention as federal regulators pursue policies intended to accelerate patient access to